Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and
may have a role in causing Kaposi's sarcoma. Valganciclovir is an antiviral drug that acts
against many types of herpesviruses and may be an effective treatment for Kaposi's sarcoma.
PURPOSE: This clinical trial is studying how well valganciclovir works in treating patients
with classic non-HIV-associated Kaposi's sarcoma.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
National Cancer Institute (NCI) New York Presbyterian Hospital University of North Carolina, Chapel Hill Weill Medical College of Cornell University